✦ LIBER ✦

Visual loss and eosinophilia after recombinant hepatitis B vaccine

✍ Scribed by AntoineP. Brézin; Marie Lautier-Frau; Mehrad Hamedani; Olivier Rogeaux; Phuc Le Hoang

Book ID: 119066359
Publisher: The Lancet
Year: 1993
Tongue: English
Weight: 318 KB
Volume: 342
Category: Article
ISSN: 0140-6736
DOI: 10.1016/0140-6736(93)91697-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Eosinophilia after intradermal hepatitis

Eosinophilia after intradermal hepatitis B vaccination

✍ Seiho Nagafuchi; Kunihiro Tokiyama; Seizaburo Kashiwagi; Shin Yayashi; Shuhei Im 📂 Article 📅 1993 🏛 The Lancet 🌐 English ⚖ 141 KB

Leucoencephalitis after recombinant hepa

Leucoencephalitis after recombinant hepatitis B vaccine

✍ Raffaele Manna; Antonella De Santis; Antonio Oliviero; Antonio Carnevale; Salvat 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Thrombocytopenic purpura after recombina

Thrombocytopenic purpura after recombinant hepatitis B vaccine

✍ P. Poullin; B. Gabriel 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 165 KB

Long-term immunity to hepatitis B infect

Long-term immunity to hepatitis B infection after vaccination with recombinant hepatitis B vaccine

✍ G.J. Boland; G.C. de Gast; E. Italiaander; J. van der Reijden; J. van Hattum 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Acute cerebellar ataxia after immunisati

Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccine

✍ F. Deisenhammer; P. Pohl; S. Bösch; C. Schmidauer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Safety and immunogenicity of a recombina

Safety and immunogenicity of a recombinant hepatitis B vaccine

✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.